AD Deal
August Debouzy advises Etherna Immunotherapies on its combination with Valerio Therapeutics to accelerate the development of targeted RNA-based therapies
August Debouzy advised Etherna Immunotherapies on its proposed acquisition by Valerio Therapeutics. The €30 million transaction, supported by a €40.25 million PIPE financing, will create an integrated biotechnology company focused on RNA-based medicines.